What is he best known for?
The fields of study he is best known for:
Cytotoxic T cell, Immunology, CD28, Antigen and IL-2 receptor are his primary areas of study.
His Cytotoxic T cell research includes elements of T cell, Protein tyrosine phosphatase and Cell biology.
His studies in Immunology integrate themes in fields like Ex vivo, In vivo and Cancer research.
The various areas that James L. Riley examines in his CD28 study include Artificial antigen presenting cells and Molecular biology.
His Antigen research is multidisciplinary, incorporating elements of Receptor, Signal transduction, Virology and T-cell receptor.
His IL-2 receptor research incorporates themes from Interleukin 21, Adoptive cell transfer, FOXP3, Autoimmunity and Transplantation.
His most cited work include:
- CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms (1178 citations)
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases (972 citations)
- The CD28 signaling pathway regulates glucose metabolism. (890 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Immunology, T cell, Cell biology, Cytotoxic T cell and CD28.
Immunology and Cancer research are frequently intertwined in his study.
His T cell study combines topics from a wide range of disciplines, such as Molecular biology, Receptor and Virology.
His research in Cytotoxic T cell intersects with topics in Epitope and CD8.
His CD28 research includes themes of T lymphocyte and CD3.
As part of one scientific family, James L. Riley deals mainly with the area of IL-2 receptor, narrowing it down to issues related to the FOXP3, and often Effector.
He most often published in these fields:
- Immunology (37.29%)
- T cell (35.59%)
- Cell biology (32.20%)
What were the highlights of his more recent work (between 2017-2021)?
- Cell biology (32.20%)
- T cell (35.59%)
- Chimeric antigen receptor (7.91%)
In recent papers he was focusing on the following fields of study:
James L. Riley focuses on Cell biology, T cell, Chimeric antigen receptor, Immune system and Cancer research.
His biological study deals with issues like Cytotoxic T cell, which deal with fields such as Epitope.
His Immune system research incorporates elements of Receptor and Antigen.
James L. Riley combines subjects such as Cancer cell, Cancer, Immunotherapy, Cytokine and Humanized mouse with his study of Cancer research.
In his research on the topic of Immunotherapy, K562 cells, IL-2 receptor and Molecular biology is strongly related with Antibody.
His study in CD28 is interdisciplinary in nature, drawing from both CD3 and Bone marrow.
Between 2017 and 2021, his most popular works were:
- Role of PD-1 during effector CD8 T cell differentiation. (121 citations)
- CAR T cells for infection, autoimmunity and allotransplantation. (73 citations)
- Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments (21 citations)
In his most recent research, the most cited papers focused on:
James L. Riley mainly investigates T cell, Cell biology, Chimeric antigen receptor, Function and Cancer.
James L. Riley interconnects Fatty acid synthesis, Transplant rejection, Fatty acid metabolism, Lipid metabolism and Effector in the investigation of issues within T cell.
His work carried out in the field of Cell biology brings together such families of science as Cell, Cellular differentiation, Transplanted tissue and T-regulatory cell.
In the field of Immunotherapy, Immunology and Immune system James L. Riley studies Chimeric antigen receptor.
The study incorporates disciplines such as Lymphoblastic lymphoma, Viral load, CD28, Antibody and CD3 in addition to Immunotherapy.
He usually deals with In vivo and limits it to topics linked to B cell and Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
